← Back to Search

Antiretroviral Therapy

B/F/TAF for HIV

Phase 1
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of delivery
Awards & highlights

Study Summary

This study is evaluating whether a combination of drugs may help treat HIV.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetic (PK) Parameter: AUCtau of BIC
Secondary outcome measures
PK Parameter: AUClast of BIC, FTC, and TAF
PK Parameter: AUCtau of emtricitabine (FTC) and tenofovir alafenamide (TAF)
PK Parameter: CL/F of BIC, FTC, and TAF
+8 more

Side effects data

From 2023 Phase 4 trial • 28 Patients • NCT03797014
18%
Upper respiratory tract infection
7%
Abdominal pain
7%
Abscess, extremity
7%
Back pain
7%
Headache
7%
Hypertension
7%
Nausea
7%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
B/F/TAF

Trial Design

1Treatment groups
Experimental Treatment
Group I: B/F/TAFExperimental Treatment1 Intervention
B/F/TAF for up to approximately 38 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
B/F/TAF
2016
Completed Phase 4
~4900

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,083 Previous Clinical Trials
843,326 Total Patients Enrolled
Gilead Study DirectorStudy DirectorGilead Sciences
343 Previous Clinical Trials
186,660 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
2019. "Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03960645.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top